Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies

Journal of General Virology

Volumn 79, Issue 1, 1998, Pages 77-82

  Beddows, Simon ^a   Louisirirotchanakul, Suda ^a   Cheingsong Popov, Rachanee ^a   Easterbrook, Philippa J ^b   Simmonds, Peter ^c   Weber, Jonathan ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; VIRUS NEUTRALIZATION; VIRUS TITRATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031964880     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-79-1-77     Document Type: Article

References (25)

1. Bou Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P. & Norcross, M. A. (1994). Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology 68, 6006-6013.
2. Boyd, M. T., Simpson, G. R., Cann, A. J., Johnson, M. A. & Weiss, R. A. (1993). A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. Journal of Virology 67, 3649-3652.
3. Cheingsong-Popov, R., Callow, D., Beddows, S., Shaunak, S., Wasi, C., Kaleebu, P., Gilks, C., Petrascu, I. V., Garaev, M. M., Watts, D. M., Constantine, N. T. & Weber, J. N. (1992). Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. Journal of Infectious Diseases 165, 256-261.
4. Cohen, J. (1993). Jitters jeopardize AIDS vaccine trials. Science 262, 980.
5. Conley, A. J., Gorny, M. K., Kessler, J. A., Boots, L. J., Ossorio Castro, M., Koenig, S., Lineberger, D. W., Emini, E. A., Williams, C. & Zolla Pazner, S. (1994). Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. Journal of Virology 68, 6994-7000.
6. Donaldson, Y. K., Bell, J. E., Holmes, E. C., Hughes, E. S., Brown, H. K. & Simmonds, P. (1994). In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. Journal of Virology 68, 5991-6005.
7. Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E. & Moore, J. P. (1997). Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with the antibody binding to the oligomeric form of the envelope glycoprotein complex. Journal of Virology 71, 2779-2785.
8. Groenink, M., Fouchier, R. A. M., Broersen, S., Baker, C. H., Koot, M., Van't-Wout, A. B., Huisman, H. G., Miedema, F., Tersmette, M. & Schuitemaker, H. (1993). Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260, 1513-1516.
9. gag and env genes. Journal of Virology 71, 1272-1280.
10. Javaherian, K., Lanlois, A. J., McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolognesi, D. P., Putney, S. D. & Matthews, T. J. (1989). Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy of Sciences, USA 86, 6768-6772.
11. Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., Clements, M. L., Dolin, R., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Walker, M. C., Wagner, K. F., McNeil, J. G., McCutchan, F. E., Burke, D. S. & NIAID AIDS Vaccine Evaluation Group (1996). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Journal of Infectious Diseases 173, 340-348.
12. Moore, J. P. (1992). MRC ADP reagent catalogue. Medical Research Council (London).
13. Moore, J. P. & Ho, D. D. (1995). HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T-cells. AIDS 9, S117-S136.
14. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. & Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology 69, 101-109.
15. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B. & Ho, D. D. (1996). Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology 70, 427-444.
16. Sawyer, L. S. W., Wrin, M. T., Crawford-Miksza, L., Potts, B., Wu, Y., Weber, P.A., Alfonso, R. D. & Hanson, C. V. (1994). Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. Journal of Virology 68, 1342-1349.
17. Sullivan, N., Sun, Y., Li, J., Hofmann, W. & Sodroski, J. (1995). Replicative function and neutralizing sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology 69, 4413-4422.
18. Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. P., Cheng-Mayer, C., Robinson, J., Maddon, P. J. & Moore, J. P. (1996). CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184-187.
19. VanCott, T. C., Bethke, F. R., Burke, D. S., Redfield, R. R. & Birx, D. L. (1995a). Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. Journal of Immunology 155, 4100-4110.
20. VanCott, T. C., Polonis, V. R., Loomis, L. D., Michael, N. L., Nara, P. L. & Birx, D. L. (1995b). Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Research and Human Retroviruses 11, 1379-1391.
21. Wang, N., Zhu, T. & Ho, D. D. (1995). Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype. Journal of Virology 69, 2708-2715.
22. Weber, J., Fenyö, E.-M., Beddows, S., Kaleebu, P., Björndal, Å. & The WHO Network for HIV Isolation & Characterization (1996). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. Journal of Virology 70, 7827-7832.
23. Wrin, T., Loh, T. P., Vennari, J. C., Schuitemaker, H. & Nunberg, J. H. (1995). Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. Journal of Virology 69, 39-48.
24. Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C. & Sodroski, J. (1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-183.
25. MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Research and Human Retroviruses 10, 245-251.